Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DMJ2N9
|
|||
| Drug Name |
Vicasinabin
|
|||
| Synonyms |
Vicasinabin; Vicasinabin [INN]; QJ8UO6C05M; RG7774; 1433361-02-4; RG-7774; (S)-1-(5-tert-Butyl-3-((1-methyl-1H-tetrazol-5-yl)methyl)-3H-(1,2,3)triazolo-(4,5-d)pyrimidin-7-yl)pyrrolidin-3-ol; 3-Pyrrolidinol, 1-(5-(1,1-dimethylethyl)-3-((1-methyl-1H-tetrazol-5-yl)methyl)-3H-1,2,3-triazolo(4,5-d)pyrimidin-7-yl)-, (3S)-; 3-Pyrrolidinol, 1-[5-(1,1-dimethylethyl)-3-[(1-methyl-1H-tetrazol-5-yl)methyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-7-yl]-, (3S)-; VICASINABIN [USAN]; UNII-QJ8UO6C05M; SCHEMBL14912040; GTPL11890; EX-A8231; AKOS040756804; Example 151 [WO2013068306A1]; HY-145604; RO6868847; CS-0376695; RO-6868847; (3S)-1-(5-(1,1-Dimethylethyl)-3-((1-methyl-1H-tetrazol-5-yl)methyl)-3H-1,2,3-triazolo(4,5-d)pyrimidin-7-yl)-3-pyrrolidinol; (3S)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol; (3S)-1-{5-tert-butyl-3-[(1-methyl-1H-tetrazol-5-yl)methyl]-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl{pyrrolidin-3-ol
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Diabetic retinopathy [ICD-11: 9B71.0; ICD-10: H36.0] | Phase 2 | [1] | |
| Company |
Roche
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H22N10O
|
|||
| Canonical SMILES |
CC(C)(C)C1=NC2=C(C(=N1)N3CCC(C3)O)N=NN2CC4=NN=NN4C
|
|||
| InChI |
InChI=1S/C15H22N10O/c1-15(2,3)14-16-12(24-6-5-9(26)7-24)11-13(17-14)25(21-19-11)8-10-18-20-22-23(10)4/h9,26H,5-8H2,1-4H3/t9-/m0/s1
|
|||
| InChIKey |
MAYZWDRUFKUGGP-VIFPVBQESA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 2 (CB2) | Target Info | Agonist | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Roche | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.